Rebecca S. Romero

Rebecca S. Romero

Auto-generated profile, based on publicly available information

Rebecca S. Romero

University of Texas Health, San Antonio, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Radiology
Verified
Journal Article
Closed access
FCFlorence L. Chiang
Florence L. Chiang
MFMax Feng
Max Feng
RRRebecca S. Romero
Rebecca S. Romero
LPLarry R Price
Larry R Price
CFCrystal G. Franklin
Crystal G. Franklin
PFPeter T. Fox
Peter T. Fox
In multiple sclerosis, disruption of the atrophy-based functional network is strongly associated with clinical disability, thereby providing support for the network degeneration hypothesis of local... Background In multiple sclerosis (MS), gray matter (GM) atrophy exhibits a specific pattern, which correlates strongly with clinical disability. However, the mechanism of regional specificity in GM...

16 June 2025 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
SWSophia Woodson
Sophia Woodson
EGEdward J. Gettings
Edward J. Gettings
CGChu-Yueh Guo
Chu-Yueh Guo
SKSylvia Klineova
Sylvia Klineova
JLJong-Mi Lee
Jong-Mi Lee
SSSai L. Shankar
Sai L. Shankar
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset disease; however, MS is not adequately studied in these groups. We compared the effectiveness of fumarates across Black, Hispanic, Asian, and white PwMS. Methods This retrospective analysis using the Komodo Health database included PwMS. Patients with a claim for diroximel fumarate or dimethyl fumarate were followed from disease-modifying therapy (DMT) initiation to loss of follow-up or discontinuation. Outcomes included annualized relapse rate (ARR), time to post-index first relapse, healthcare resource use (HRU), healthcare costs (HCCs), and change in absolute lymphocyte counts (ALCs). Race/ethnicity was self-reported. Results This study included 6800 PwMS (Black, n = 1241; Hispanic, n = 777; Asian, n = 132; white, n = 4650). The average exposure duration of fumarates was 449–559 days. Black PwMS had higher baseline disease burden versus white PwMS, were less likely to have commercial insurance plans, and were more likely to reside in a state with a higher poverty rate. ARRs (12-month pre-index to post-index) were significantly reduced across groups. The Kaplan–Meier estimated proportion of relapse-free patients at 2 years was similar across groups (Black, 77.0%; Hispanic, 75.4%; Asian, 81.7%; white, 80.5%). There was a smaller decline in ALC from month 0 to month 12 in Black PwMS versus other racial/ethnic groups. Conclusion Consistent with prior studies, these results demonstrate the effectiveness of fumarates across racial and ethnic MS subgroups. This is the largest analysis to date of the treatment effects of any individual class of DMT in Black and Hispanic PwMS. Infographic available for this article.

12 February 2013 in Neurology
Verified
Journal Article
Closed access
JBJacqueline Bernard
Jacqueline Bernard
RRRebecca Romero
Rebecca Romero
KAKhushboo Agrawal
Khushboo Agrawal
RJRama Jager
Rama Jager
KRKourosh Rezania
Kourosh Rezania